ZEISS Advances Ophthalmic Surgical Innovation in Mexico With New 3D Visualization and Lens Removal Technologies

ZEISS Advances Ophthalmic Surgical Innovation in Mexico With New 3D Visualization and Lens Removal Technologies

(IN BRIEF) Carl Zeiss Meditec has received regulatory approval from Mexico’s COFEPRIS authority for the ZEISS ARTEVO 850 ophthalmic surgical microscope and the ZEISS MICOR 700 lens removal device. The newly approved technologies expand ZEISS’s ophthalmic surgery portfolio in Mexico and support integrated cataract surgery workflows with advanced digital visualization and ultrasound-free lens extraction capabilities. The systems are designed to improve surgical precision, operating room efficiency, and workflow integration for ophthalmic procedures. ZEISS plans to showcase both technologies at the upcoming Mexican Congress of Ophthalmology in Monterrey.

(PRESS RELEASE) OBERKOCHEN, 14-May-2026 — /EuropaWire/ — Carl Zeiss Meditec announced that Mexico’s health regulatory authority, Comisión Federal para la Protección contra Riesgos Sanitarios (COFEPRIS), has approved the ZEISS ARTEVO® 850 ophthalmic surgical microscope and the ZEISS MICOR® 700 lens removal device for the Mexican market.

The approvals expand ZEISS Medical Technology’s ophthalmic surgery portfolio in Mexico and strengthen the company’s cataract surgery workflow offering with integrated visualization and surgical technologies designed to improve operating room efficiency and surgical precision.

Both technologies are compatible with the latest generation of ZEISS cataract surgery workflows and will be presented during the XXXVIII Mexican Congress of Ophthalmology in Monterrey from 30 May to 3 June 2026.

PT Cheong, Head of Global Sales for Ophthalmology at ZEISS Medical Technology, stated that the company continues expanding its global ophthalmic portfolio by introducing advanced surgical technologies into regional healthcare markets such as Mexico. He noted that the investment aims to support local surgeons with improved visualization and operating room capabilities to enhance patient eye care.

Frank Seitzinger, Head of Business Sector Surgery Anterior Segment at ZEISS Medical Technology, described both the ZEISS MICOR 700 and ZEISS ARTEVO 850 as important advancements for cataract surgery workflows, improving both surgical visualization and operating room efficiency.

The ZEISS ARTEVO 850 is a digital 3D ophthalmic surgical microscope designed to enhance visualization during eye surgery procedures. According to the company, the system provides true-color imaging and increases depth of field by nearly 60%, supporting more detailed surgical views during ophthalmic procedures.

The microscope also integrates with ZEISS ophthalmic workflow systems, allowing seamless digital data transfer between connected surgical devices. The ARTEVO 850 equipped with CALLISTO eye® additionally includes a redesigned touchscreen user interface intended to centralize and simplify surgical controls during operations.

The ZEISS MICOR 700 introduces a hand-held ultrasound-free lens removal system for cataract surgery. The device uses the company’s proprietary NULEX (non-ultrasonic lens extraction) procedure, which is designed to help surgeons increase intraocular working space while minimizing risks to surrounding eye structures.

The system’s blunt-tip design with rounded edges is intended to reduce the likelihood of tissue damage during lens extraction procedures. ZEISS stated that the MICOR 700 also incorporates a disposable “plug-and-play” system intended to simplify operating room workflows and reduce equipment complexity.

The approvals reflect continued investment in advanced ophthalmic surgical technologies as healthcare providers seek improved precision, workflow integration, and efficiency in cataract and eye surgery procedures.

Headquartered in Jena, Carl Zeiss Meditec develops medical technologies focused on ophthalmology, microsurgery, and vision care solutions for healthcare providers worldwide.

For more information about ZEISS ophthalmic workflow solutions in Mexico, visit here.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of €2,228m in fiscal year 2024/25 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company’s presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For more information visit our website at www.zeiss.com/med

Media Contacts:

Press & Investor Relations:
Sebastian Frericks
Head of Group Finance & Investor Relations
Carl Zeiss Meditec AG
investors.med@zeiss.com
Tel:+49 3641 220 116

Press:
Frank Smith
Head of Global Communications Ophthalmology
Carl Zeiss Meditec Inc.
Tel:+49 3641  220 331
press.med@zeiss.com

SOURCE: Zeiss